Positive Effects of Haematococcus Astaxanthin on Oxidative Stress and Lipid Profile in Overweight and Obese Adults

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Seoul National University Hospital.
Recruitment status was  Not yet recruiting
Ministry of Health & Welfare, Korea
Information provided by:
Seoul National University Hospital
ClinicalTrials.gov Identifier:
First received: July 8, 2010
Last updated: July 20, 2010
Last verified: July 2010
The purpose of this study is to determine whether astaxanthin (ASX) supplementation will reduce obesity-induced oxidative stress and improve lipid profile in overweight and obese adults.

Condition Intervention
Dietary Supplement: astaxanthin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • Evaluation of the plasma MDA (malonaldehyde) level [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

    MDA is a three chain aldehyde produced during the composition of a lipid hydroperoxide and is a well known indicator of lipid peroxidation.

    The purpose of this stduy is to determine whether ASX supplementation lowers oxidative stress using MDA,a biomarker.

Estimated Enrollment: 30
Study Start Date: August 2010
Estimated Study Completion Date: March 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Dietary Supplement: astaxanthin
    astaxanthin 20mg for 12 weeks

Ages Eligible for Study:   19 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects with BMI over 25.0 kg/m2
  • Non-smoker

Exclusion Criteria:

  • Excessive alcohol consumption
  • Pregnant or lactating women
  • Dyslipidemia, hyperglycemia, or other chronic diseases.
  • Subjects who were taking vitamin supplements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01167205

Contact: Yeo-kyu Youn, Doctor +82 2 2072 3447 ykyoun@snu.ac.kr

Korea, Republic of
Clinical Research Institute Seoul National University Hospital Not yet recruiting
Seoul, Korea, Republic of, 110-744
Contact: Wan Gyoon Shin, Ph D, Pharm D    +82 2 740 85556    wgshin@snu.ac.kr   
Sponsors and Collaborators
Seoul National University Hospital
Ministry of Health & Welfare, Korea
  More Information

ClinicalTrials.gov Identifier: NCT01167205     History of Changes
Other Study ID Numbers: C-1005-072-319 
Study First Received: July 8, 2010
Last Updated: July 20, 2010
Health Authority: Korea: Food and Drug Administration

Keywords provided by Seoul National University Hospital:
Healthy adults with BMI over 25.0 kg/m2

Additional relevant MeSH terms:
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on May 04, 2016